InvestorsHub on MSN

Stoke Therapeutics shares slide after updated Phase 3 timeline

Shares of Stoke Therapeutics (NASDAQ:STOK) fell about 18% after the company outlined revised timelines for its Phase 3 ...
STAT

FDA puts off Stoke’s request for faster filing of severe epilepsy drug

Stoke Therapeutics and the FDA were unable to reach agreement on an expedited submission for the company’s severe epilepsy ...

Cisse s late strike sends Stoke to the next round

Stoke City reached the FA Cup fourth round thanks to a sensational 25-yard half-volley from Lamine Cisse in the dying minutes ...

Stoke Therapeutics stock falls after delayed Phase 3 readout timeline

The biotechnology company now expects to complete enrollment of 150 patients in the second quarter of 2026, with data readout anticipated in mid-2027. Stoke plans to initiate a rolling New Drug ...

Southampton Star Set to Join Stoke City on Loan With £8m Option to Buy

Bazunu is likely to fall down the pecking order at Southampton after they completed the signing of Bayern Munich goalkeeper ...
FierceBiotech

Stoke's Dravet syndrome med released from partial clinical hold as company eyes phase 3 plans

Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program. While studies for STK-001, now known as zorevunersen, had ...
FierceBiotech

Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...